Business development is an essential process for biotech companies to build relationships with partners and create value from the deal structures that are based on science. We are taking a deep dive with James Lee into the mechanics and the framework that James uses for business development. 

James founded Bridge Biotherapeutics Inc. in 2015 and he currently serves as the CEO. Bridge has been recognized with the continuous advancement of clinical-stage programs focused on pulmonary fibrosis, lung cancer, and immunology. In 2019, James successfully orchestrated the licensing-out deal with Boehringer Ingelheim, which marked as one of the largest global deals on a single compound in Korea.